Oxygen Biotherapeutics jumps on issuance of patent for its treatment of pruritus

|By:, SA News Editor

Oxygen Biotherapeutics (OXBT +20%) pops after the USPTO issued the drug developer a patent earlier today for its treatment for pruritus - a sensation patients instinctually try to relieve by rubbing or scratching.

The company says it's currently evaluating commercialization strategies, which potentially includes out-licensing for conditions such as allergic contact dermatitis, psoriasis and acne.